Novartis Beats EPO Challenge To Eye-Drop Medication Patent
Novartis has fended off the challenges of two pharmaceutical rivals to its patent for an eye-drop medication as European officials concluded that the drugmaker's combination of key components differed from an...To view the full article, register now.
Already a subscriber? Click here to view full article